Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06966583 | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC(NMN) | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 12, 2025 | clinicaltrials |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2025 |
| NCT06962189 | The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study | not yet recruiting | Phase 2 | 39 | Zhejiang UniversityOTHER | 0 | May 8, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT06946836 | Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study(Neoadjuvant) | not yet recruiting | Phase 2 | 80 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06934590 | Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC | not yet recruiting | Phase 1 | 18 | GeneCraft Inc.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06925048 | SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC | not yet recruiting | Phase 2 | 86 | Chunxia SuOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06922266 | Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option(Chewbacca) | not yet recruiting | — | 20 | Ospedale San RaffaeleOTHER | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06908733 | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC | not yet recruiting | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06775002 | SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type | not yet recruiting | — | 223 | Fuzhou General HospitalOTHER | 0 | Mar 31, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06890182 | Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | not yet recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06885840 | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | not yet recruiting | Phase 2 | 100 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06856798 | Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective | not yet recruiting | — | 120 | Ziming LiOTHER | 0 | Mar 4, 2025 | clinicaltrials |
| NCT06854939 | A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.(MRDSEEKER) | not yet recruiting | — | 350 | National Cancer Center, JapanOTHER_GOV | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06851169 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response | not yet recruiting | Phase 2 | 58 | Tang-Du HospitalOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT03514329 | Vapor Ablation for Localized Cancer Lesions(VAPORIZED) | not yet recruiting | N/A | 10 | Uptake Medical Technology, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT06848426 | Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial | not yet recruiting | N/A | 100 | Jiangxi Provincial People's HopitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06847334 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 772 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 26, 2025 | clinicaltrials |
| NCT06837948 | Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06828757 | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 94 | Hunan Province Tumor HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06818955 | Orlistat Overcoming Third-generation EGFR-TKI Resistance(OOTER) | not yet recruiting | Phase 2 | 36 | Ping PengOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06823245 | Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06823258 | Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06786208 | Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure | not yet recruiting | — | 55 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06779539 | Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 33 | West China HospitalOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT06780839 | Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD | not yet recruiting | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06725537 | Comprehensive Demographics and Clinical Profile of NSCLC Patients(CA209-1529) | not yet recruiting | — | 500 | D'Or Institute for Research and EducationOTHER | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06775483 | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | not yet recruiting | Phase 2 | 220 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06768853 | The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models | not yet recruiting | N/A | 60 | Zhongnan HospitalOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06766591 | Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs | not yet recruiting | N/A | 36 | Jiangsu Province Nanjing Brain HospitalOTHER | 0 | Jan 9, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06757114 | A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas | not yet recruiting | — | 200 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06672068 | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC | not yet recruiting | Phase 2 | 60 | TYK Medicines, IncINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06752408 | Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer(ANOTHER) | not yet recruiting | Phase 2 | 316 | Peking Union Medical College HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06746870 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 148 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06738680 | PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1(PROFIL-1) | not yet recruiting | — | 120 | University Hospital, BrestOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06739421 | The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial | not yet recruiting | N/A | 1,040 | China-Japan Friendship HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06704620 | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 430 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735508 | MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | not yet recruiting | Early Phase 1 | 40 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06736561 | A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients. | not yet recruiting | — | 100 | Harbin Medical UniversityOTHER | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06709274 | Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC(MOTION-NSCLC) | not yet recruiting | N/A | 342 | Guangdong Association of Clinical TrialsOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06694129 | Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC | not yet recruiting | — | 40 | National Cancer Center, ChinaOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06690541 | Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC(COMLORLA) | not yet recruiting | — | 100 | Peking University Cancer Hospital & InstituteOTHER | 0 | Nov 15, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06685653 | Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients | not yet recruiting | Early Phase 1 | 65 | Nanjing Tianyinshan HospitalOTHER | 0 | Nov 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2025source: clinicaltrials